Literature DB >> 21527371

Ten cases of drug reaction with eosinophilia and systemic symptoms (DRESS) treated with pulsed intravenous methylprednisolone.

Janakan Natkunarajah1, Sacha Goolamali, Emma Craythorne, Emma Benton, Catherine Smith, Rachael Morris-Jones, Julia Wendon, Elisabeth Higgins, Daniel Creamer.   

Abstract

Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare, life-threatening, drug-induced illness characterised by a widespread polymorphic eruption, fever and multivisceral involvement. There is little published on the management of DRESS. Prompt recognition and withdrawal of the causative drug is essential, along with supportive treatment. However, the condition commonly progresses despite these measures. Oral corticosteroids are usually given but the response can be suboptimal and result in a prolonged exposure to systemic glucocorticoid. We conducted a prospective single-centre study to determine the efficacy of pulsed intravenous methylprednisolone followed by a short reducing course of oral prednisolone in ten patients with confirmed DRESS. Rash and fever responded rapidly to methylprednisolone in all patients. Compared to pre-treatment assessments, there was a significant reduction in eosinophil count at day 14 and AST level at day 90 post-treatment. One patient developed acute hepatic failure, necessitating a liver transplant, and died 4 months later. In the immediate post-treatment phase, 1 patient developed type 1 diabetes and 1 patient developed a corticosteroid-induced psychosis. Long-term follow-up on 8/10 revealed all patients to be well, although one patient had persistent pruritus. An aggressive corticosteroid regimen in the management of DRESS is associated with good clinical outcome and acceptable tolerance.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21527371     DOI: 10.1684/ejd.2011.1300

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   3.328


  6 in total

1.  DRESS syndrome associated with type 2 diabetes in a child.

Authors:  Semiha Bahceci Erdem; Hikmet Tekin Nacaroglu; Ozlem Bag; Canan Sule Unsal Karkiner; Huseyin Anil Korkmaz; Demet Can
Journal:  Cent Eur J Immunol       Date:  2016-01-15       Impact factor: 2.085

Review 2.  Updates and Insights in the Diagnosis and Management of DRESS Syndrome.

Authors:  Elisa Maria Schunkert; Sherrie Jill Divito
Journal:  Curr Dermatol Rep       Date:  2021-11-09

3.  Severe Toxic Epidermal Necrolysis and Drug Reaction with Eosinophilia and Systemic Symptoms Overlap Syndrome Treated with Benralizumab: A Case Report.

Authors:  Felix K Zeller; Patrick R Bader; Mirjam C Nägeli; Philipp K Buehler; Reto A Schuepbach
Journal:  Case Rep Dermatol       Date:  2022-07-14

Review 4.  Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012.

Authors:  Sheena N Ramasamy; Cameron S Korb-Wells; Diluk R W Kannangara; Myles W H Smith; Nan Wang; Darren M Roberts; Garry G Graham; Kenneth M Williams; Richard O Day
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.228

5.  Successful treatment of drug reaction with eosinophilia and systemic symptoms syndrome relapse with oral pulsed dexamethasone.

Authors:  Claire-Audrey Y Bayan; Adriana Lopez; Natalia M Fontecilla; Larisa J Geskin
Journal:  JAAD Case Rep       Date:  2018-10-13

6.  Drug reaction with eosinophilia and systemic symptoms (DRESS) in children.

Authors:  Francesca Mori; Carlo Caffarelli; Silvia Caimmi; Paolo Bottau; Lucia Liotti; Fabrizio Franceschini; Fabio Cardinale; Roberto Bernardini; Giuseppe Crisafulli; Francesca Saretta; Elio Novembre
Journal:  Acta Biomed       Date:  2019-01-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.